Mesenchymal stem cells for treating GVHD: In-vivo fate and optimal dose

Subbanna, Prasanna Kumar T

doi:10.1016/j.mehy.2006.12.016

Cited by 32 publications

(24 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The minimal and maximal dosages for therapeutic application has not been determined yet, but currently applied doses are in the range of <1–5 × 10 6 MSCs/kg body weight (142). Koç et al have found that intravenously adoptive MSCs are well-tolerated in patients with mammary carcinoma at a dose of 1 × 10 6 MSCs/kg body weight (143).…”

Section: Pitfalls In Using Mscs To Treat Atherosclerosismentioning

confidence: 99%

Function and Therapeutic Potential of Mesenchymal Stem Cells in Atherosclerosis

Guo

Chen

2017

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Atherosclerosis is a complicated disorder and largely attributable to dyslipidaemia and chronic inflammation. Despite therapeutic advances over past decades, atherosclerosis remains the leading cause of mortality worldwide. Due to their capability of immunomodulation and tissue regeneration, mesenchymal stem cells (MSCs) have evolved as an attractive therapeutic agent in various diseases including atherosclerosis. Accumulating evidences support the protective role of MSCs in all stages of atherosclerosis. In this review, we highlight the current understanding of MSCs including their characteristics such as molecular markers, tissue distribution, migratory property, immune-modulatory competence, etc. We also summarize MSC functions in animal models of atherosclerosis. MSC transplantation is able to modulate cytokine and chemokine secretion, reduce endothelial dysfunction, promote regulatory T cell function, decrease dyslipidemia, and stabilize vulnerable plaques during atherosclerosis development. In addition, MSCs may migrate to lesions where they develop into functional cells during atherosclerosis formation. Finally, the perspectives of MSCs in clinical atherosclerosis therapy are discussed.

show abstract

Section: Pitfalls In Using Mscs To Treat Atherosclerosismentioning

confidence: 99%

Function and Therapeutic Potential of Mesenchymal Stem Cells in Atherosclerosis

Guo

Chen

2017

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Currently applied doses are in 1-5 millions MSC/kg body weight range (Subbanna, 2007), thus a fast and reliable ex vivo expansion method is needed to meet the highly demanding cell dose.…”

Section: Introductionmentioning

confidence: 99%

Maximizing the ex vivo expansion of human mesenchymal stem cells using a microcarrier-based stirred culture system

Eibes

Santos

Andrade

et al. 2010

Journal of Biotechnology

156

110

View full text Add to dashboard Cite

“…Although the optimal amount of MSCs is yet to be determined, standard applied MSC doses range from less than one to up to five million MSCs per kg body weight [10]. The low in vivo frequency of MSCs [11] necessitates ex vivo expansion to obtain transplantable numbers.…”

Section: Introductionmentioning

confidence: 99%

Platelet-derived growth factors for GMP-compliant propagation of mesenchymal stromal cells

Schallmoser

Rohde

Bartmann

et al. 2009

Bio-Medical Materials and Engineering

View full text Add to dashboard Cite

Stem cell-based therapies are a promising prospect for regenerative medicine. Particularly, human multipotent mesenchymal stromal cells (MSCs) are currently in focus regarding their regenerative and immune modulating capacities. An increasing number of clinical trials investigating MSC efficiency and safety are ongoing. Ex vivo propagation of human MSCs is considered to be a prerequisite for MSC therapy. The to date standard use of fetal bovine serum in cell culture bears risks including xenoimmunization and transmission of pathogens. Alternatively, human platelet-derived growth factors have been efficiently implemented into routine MSC expansion protocols. In compliance with good manufacturing practice we established an effective time-and resource-saving procedure for MSC propagation in an animal serum-free system. Bone marrow was seeded without manipulation directly in pooled human platelet lysate (pHPL) and L-glutamine supplemented minimum essential medium without antibiotics. Clinical scale expanded MSCs were harvested already after primary culture. MSC quality, identity, purity and function were assessed according to a defined panel of release criteria and comparative genomic hybridization was used to determine genomic stability. Because various potential risks of MSCs have recently been reported, further research is required to prove efficiency and long-term safety of human MSCs for cell therapy.

show abstract

Mesenchymal stem cells for treating GVHD: In-vivo fate and optimal dose

Cited by 32 publications

References 6 publications

Function and Therapeutic Potential of Mesenchymal Stem Cells in Atherosclerosis

Function and Therapeutic Potential of Mesenchymal Stem Cells in Atherosclerosis

Maximizing the ex vivo expansion of human mesenchymal stem cells using a microcarrier-based stirred culture system

Platelet-derived growth factors for GMP-compliant propagation of mesenchymal stromal cells

Contact Info

Product

Resources

About